LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Future Oncol
; 19(40): 2631-2640, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-37882432
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Kidney Neoplasms
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Future Oncol
Year:
2023
Type:
Article
Affiliation country:
United States